FULC Stock Summary and Trading Ideas (Fulcrum Therapeutics | NASDAQ:FULC)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics trades on the NASDAQ stock market under the symbol FULC.

As of March 5, 2025, FULC stock price declined to $3.25 with 397,142 million shares trading.

FULC has a beta of -1.23, meaning it tends to be less sensitive to market movements. FULC has a correlation of 0.02 to the broad based SPY ETF.

FULC has a market cap of $175.30 million. This is considered a Micro Cap stock.

In the last 3 years, FULC traded as high as $24.79 and as low as $2.25.

The top ETF exchange traded funds that FULC belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

FULC has underperformed the market in the last year with a price return of -71.3% while the SPY ETF gained +15.2%. FULC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.4% and -13.8%, respectively, while the SPY returned -3.7% and -4.6%, respectively.

FULC support price is $3.13 and resistance is $3.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FULC shares will trade within this expected range on the day.